Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML

Abstract: Despite the use of FMS-like tyrosine kinase 3 (FLT3) inhibitors, outcomes for patients with FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) remain suboptimal because of high rates of relapse. We evaluated the safety and efficacy of the combination of daunorubicin, cytarabine (DA), gemt...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Nigel Russell, Jad Othman, Oliver Cumming, Abin Thomas, Aditya Tedjaseputra, Nicola Potter, Jelena Jovanovic, Amanda Gilkes, Leona Batten, Joanna Canham, Emily Hinson, Manohursingh Runglall, Phoebe Aucken, Panos Kottaridis, Jamie Cavenagh, Claire Arnold, Sylvie Freeman, Mike Dennis, Steven Knapper, Richard Dillon
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-12-01
Serie:	Blood Advances
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2473952925005956
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!